UPDATE 1-Acorda Therapeutics posts profit on MS walking drug

* Q3 EPS $0.31 vs est $-0.12

* Q3 rev $63.6 mln vs est $52.2 mln

Nov 1 (BestGrowthStock) – Acorda Therapeutics Inc (ACOR.O: ) posted
its first quarterly profit in at least three years, surprising
Wall Street analysts, on continued robust sales of its key drug
Ampyra.

For the third quarter, the Hawthorne, New York-based
company posted a net income of $12.4 million, or 31 cents a
share, compared to a net loss of $19.4 million, 51 cents a
share, a year ago.

The pharmaceutical company reported revenue of $63.6
million in the quarter, of which $52.6 million came from sales
of Ampyra. The drug was launched in March to treat walking
difficulties in patients with multiple sclerosis.

Analysts expected the company to post a loss of 12 cents a
share, before special items, on revenue of $52.2 million,
according to Thomson Reuters I/B/E/S.

Adoption of Ampyra continued at a robust pace with about
6,300 physicians having written at least one prescription for
the drug, as of Sept. 30, the company said in a statement.

As of July 30, more than 4,200 physicians had written at
least one prescription for Ampyra, Acorda had said in August.

Acorda shares, which have lost about 18 percent since the
company reported its second-quarter results in August, had
closed at $27.04 Friday on Nasdaq.
(Reporting by Vidya L Nathan in Bangalore; Editing by Aradhana
Aravindan)

UPDATE 1-Acorda Therapeutics posts profit on MS walking drug